【#辉瑞宣布其新冠实验性药物可将新冠重症及死亡率减少89%#】辉瑞公司11月5日表示，该公司研发的针对新冠病毒的实验性抗病毒药物，被证明可将新冠引起的重症和死亡率减少89%。辉瑞公司表示，它计划向美国食品和药物管理局（FDA）提交其药物的中期试验结果。Pfizer Inc on Friday said its experimental antiviral pill for COVID-19 has shown to cut the chances of hospitalization or death for adults at risk of developing the severe disease by 89 percent. Pfizer also added that it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.
